STAGNO, Fabio
 Distribuzione geografica
Continente #
NA - Nord America 1.609
EU - Europa 976
AS - Asia 849
SA - Sud America 187
AF - Africa 176
Continente sconosciuto - Info sul continente non disponibili 78
OC - Oceania 2
Totale 3.877
Nazione #
US - Stati Uniti d'America 1.558
RU - Federazione Russa 410
SG - Singapore 393
IT - Italia 250
CN - Cina 204
BR - Brasile 163
CI - Costa d'Avorio 111
IE - Irlanda 92
VN - Vietnam 83
IN - India 43
DE - Germania 41
FR - Francia 38
CA - Canada 36
KR - Corea 28
SN - Senegal 28
GB - Regno Unito 27
UA - Ucraina 23
FI - Finlandia 16
IQ - Iraq 14
NL - Olanda 14
SE - Svezia 14
NG - Nigeria 12
TR - Turchia 12
AR - Argentina 11
BD - Bangladesh 11
UZ - Uzbekistan 11
ZA - Sudafrica 10
ES - Italia 9
JP - Giappone 9
MX - Messico 9
KE - Kenya 8
PL - Polonia 8
CZ - Repubblica Ceca 7
HK - Hong Kong 7
AE - Emirati Arabi Uniti 6
BE - Belgio 5
PY - Paraguay 5
AT - Austria 4
MY - Malesia 4
SA - Arabia Saudita 4
DO - Repubblica Dominicana 3
EC - Ecuador 3
GR - Grecia 3
ID - Indonesia 3
KZ - Kazakistan 3
LB - Libano 3
MA - Marocco 3
NO - Norvegia 3
PE - Perù 3
AU - Australia 2
CL - Cile 2
CY - Cipro 2
EG - Egitto 2
HU - Ungheria 2
JO - Giordania 2
LT - Lituania 2
RO - Romania 2
AZ - Azerbaigian 1
BJ - Benin 1
CH - Svizzera 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
HR - Croazia 1
IR - Iran 1
JM - Giamaica 1
LU - Lussemburgo 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PK - Pakistan 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 3.800
Città #
Singapore 257
Dallas 243
Moscow 206
Santa Clara 205
Chandler 169
San Jose 112
Abidjan 111
Chicago 101
Ashburn 91
Dublin 91
Catania 60
Los Angeles 53
Beijing 49
Hefei 44
Civitanova Marche 33
Boardman 32
Seoul 28
Dakar 27
Lauterbourg 27
Houston 25
Kochi 25
New York 25
Cambridge 23
Lawrence 23
Andover 22
Ho Chi Minh City 21
São Paulo 20
Hanoi 18
Jacksonville 18
Buffalo 15
Council Bluffs 15
Dong Ket 14
Munich 14
Orem 14
Des Moines 13
Grafing 13
Montreal 13
Palermo 13
The Dalles 13
Nanjing 12
Wilmington 12
Columbus 9
Johannesburg 9
Milan 9
Toronto 9
Amsterdam 8
Ottawa 8
Tokyo 8
Brooklyn 7
Turku 7
Abuja 6
Bari 6
Belo Horizonte 6
Denver 6
Hanover 6
London 6
Poplar 6
Saint Petersburg 6
Tashkent 6
Baghdad 5
Boston 5
Curitiba 5
Falls Church 5
Giardini-Naxos 5
Haiphong 5
Helsinki 5
Hong Kong 5
Jiaxing 5
Lagos 5
Nairobi 5
Rio de Janeiro 5
Rome 5
Stockholm 5
Warsaw 5
Asunción 4
Brno 4
Brussels 4
Dubai 4
Elk Grove Village 4
Frankfurt am Main 4
Hebei 4
Jinan 4
Lappeenranta 4
Nanchang 4
Paris 4
Santa Venerina 4
Seattle 4
Acalanes Ridge 3
Atlanta 3
Belém 3
Bremen 3
Florence 3
Istanbul 3
Juiz de Fora 3
Mumbai 3
Osasco 3
Phoenix 3
Piscataway 3
Roseto degli Abruzzi 3
Tremestieri Etneo 3
Totale 2.614
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 228
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 182
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 171
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 164
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 161
A case of high-risk AML in a patient with advanced systemic mastocytosis 158
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 158
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 156
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside 151
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 149
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 148
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 146
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 145
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 145
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 144
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 132
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 129
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 128
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 128
Differences among young adults, adults and elderly chronic myeloid leukemia patients 125
Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients 124
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 120
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 116
Evaluation of taxol cytotoxicity on B-CLL cells in vitro 114
Uncommon long-term survival in a patient with chronic myeloid leukemia 111
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 97
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper 73
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 66
Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs 8
Totale 3.877
Categoria #
all - tutte 12.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.445


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022164 4 24 3 3 34 5 27 4 9 1 9 41
2022/2023432 28 48 16 50 31 64 1 80 85 5 18 6
2023/2024251 13 40 8 12 8 66 1 15 5 10 50 23
2024/2025902 12 147 37 83 171 115 77 36 34 52 90 48
2025/20261.815 106 125 264 133 264 460 149 19 124 117 33 21
2026/202736 36 0 0 0 0 0 0 0 0 0 0 0
Totale 3.877